Atlas Trials

A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Clinical trial NCT03873025 · WITHDRAWN

Trial details

NCT number
NCT03873025
Sponsor
University College, London
Status
WITHDRAWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Diffuse Large B Cell Lymphoma
Start date
2019-10-01
Primary completion
2024-04-01
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.